Overview

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Status:
RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of BEBT-209 in combination with fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer.

Phase:

PHASE3

Details

Lead Sponsor:

BeBetter Med Inc

Collaborator:

Chinese Academy of Medical Sciences

Treatments:

Fulvestrant